Strados Labs Forms Collaboration with Boehringer Ingelheim for its IPF Pilot Study

257

Strados Labs announced a collaboration with Boehringer Ingelheim to remotely monitor patients using its FDA-cleared pulmonary wearable device in an upcoming idiopathic pulmonary fibrosis (IPF) pilot study. In Boehringer Ingelheim’s pilot study, the Strados RESP Biosensor will be used to monitor cough and crackles in IPF patients at home aiming to accelerate the development of much needed new therapies for people living with IPF.

Research has suggested that cough may be associated with worse outcomes in pulmonary fibrosis. Boehringer Ingelheim will assess how monitoring cough and crackles with the RESP Biosensor can be used to monitor the status of patients with this disease, with the aim of advancing clinical research and the development of next therapies to transform the lives of people with pulmonary fibrosis.

“Currently, disease progression in IPF is measured by a decline in forced vital capacity (FVC).” Says Strados Labs CEO & Cofounder Nick Delmonico. “We are thrilled to help Boehringer Ingelheim explore cough and crackles as an additional method to monitor disease while allowing patients to stay in the comfort of their homes.”

The RESP Biosensor is a lightweight, non-invasive wearable device that is used in clinical trials to monitor cough frequency, severity, and type along with wheezing and other abnormal sounds. The device is also used for remote monitoring in healthcare to address the problem of patient readmissions associated with COPD, asthma, and other cardiopulmonary diseases.